N- (1,2,3,5,6,7- hexahydro- S- indacen- 4- ylcarbamoyl)- 4- (2- hydroxy- 2- propanyl)- 2- furansulfonamide

01/01/2022 - "After MCC950 treatment, mdx mice exhibited a significant reduction of inflammation, macrophage infiltration and oxidative stress (-20 to -65%, P<0.05 vs untreated mdx). "
12/01/2019 - "Specific NLRP3 inhibition in vivo with MCC950 inhibited IL-1β in the lungs of CF mice (P < 0.0001), resulting in significantly reduced airway inflammation and improved Pseudomonas clearance (P < 0.0001).Conclusions: CF neutrophil immunometabolism is altered in response to inflammation. "
01/01/2021 - "Administration of MCC950 suppressed inflammation and improved right ventricular function. "
05/01/2022 - "This review summarized the structure and mechanism of action of MCC950 in the control of NLRP3-dependent inflammation and the role of MCC950 in the treatment of NLRP3-mediated inflammatory diseases based on the latest studies."
12/01/2023 - "Meanwhile, the neuroprotection, anti-inflammation, and anti-apoptosis effects of Neuritin were enhanced by MCC950 but partly counteracted by MSU. "

12/01/2022 - "At the same time, MCC950 can inhibit excessive proliferation of cells, which is beneficial for alleviating corneal fibrosis healing."
11/01/2021 - "The results showed that MCC950 co-treatment significantly improved myocardial function, inhibited inflammatory and myocardial fibrosis, and attenuated cardiomyocyte pyroptosis in DOX-treated mice. "
09/01/2019 - "In this study, we evaluated the effect of MCC950, as a potential new treatment strategy for MI, on myocardial fibrosis and cardiac remodeling using an experimental mouse model. "
11/12/2022 - "Targeting pyroptosis by inhibitor MCC950 attenuated the severity and ameliorated liver function in fibrosis models. "
09/01/2019 - "MCC950, as a specific NLRP3 inhibitor, can alleviate fibrosis and improve cardiac function in a mouse model by suppressing early inflammatory responses post-MI."

01/01/2022 - "The behavioral tests including Y-maze, Barnes maze, nest building and Rotarod showed that MCC950 significantly improved the cognitive dysfunction symptom without affecting the motor coordination after consecutive intragastric administration every day for 5 weeks. "
10/01/2023 - "MCC950 was injected intraperitoneally 1 h after SAH at a dose of 10 mg/kg. The results showed that MCC950 significantly attenuated white matter microstructure damage in some brain regions, and behavioral experiments confirmed that MCC950 ameliorated cognitive function in rats after SAH, which may provide a new method for the treatment of cognitive dysfunction in SAH patients."
02/19/2020 - "Notably, administration with MCC950 attenuated inflammatory changes and rescued surgery-induced cognitive impairments. "
10/01/2023 - "Treatment with the NLRP3 inhibitor MCC950 following chemotherapy significantly reduced cognitive impairment and decreased the expression of NLRP3, caspase-1 and ASC. "
11/29/2023 - "MCC950 effectively suppressed STZ-induced cognitive impairment and anxiety by inhibiting NLRP3-dependent neuroinflammation. "

01/01/2020 - "Importantly, we showed that chronic administration of MCC950, a novel selective NLRP3 inhibitor, to gp120 transgenic mice not only attenuated neuroinflammation and neuronal death but also promoted neuronal regeneration and restored the impaired neurocognitive function. "
01/01/2018 - "The effects of MCC950 on mice with TBI were then determined using post-assessments including analyses of neurological deficits, brain water content, traumatic lesion volume, neuroinflammation, blood-brain barrier (BBB) integrity, and cell death. "
02/26/2022 - "Most importantly, oral administration of MCC950 increased neuronal survival, reduced neuroinflammation, extended lifespan, and improved motor dysfunction in R6/2 mice. "
11/29/2023 - "MCC950 effectively suppressed STZ-induced cognitive impairment and anxiety by inhibiting NLRP3-dependent neuroinflammation. "
11/29/2023 - "MCC950 reduces autophagy and improves cognitive function by inhibiting NLRP3-dependent neuroinflammation in a rat model of Alzheimer's disease."

01/01/2018 - "MCC950 treatment provided a significant improvement in neurological function and reduced cerebral edema in TBI animals. "
06/15/2020 - "MCC950 improved cerebral edema and alleviated the damage of BBB after tMCAO. "
01/01/2019 - "MCC950 was injected intraperitoneally 1 h after SAH with a dose of 10 mg/kg. The results showed that MCC950 significantly ameliorated severe brain edema and neurological dysfunction. "
01/01/2018 - "MCC950 treatment resulted in a better neurological outcome after TBI by alleviating brain edema, reducing lesion volume, and improving long-term motor and cognitive functions. "
11/01/2021 - "Post-resuscitation brain edema was significantly reduced in animals treated with MCC950 (p < 0.05). "